Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this observational study is to identify progressive changes of quantitative brain and lung imaging, serum and movement-related biomarkers reflecting disease progression in pre-symptomatic infants and very young children (0-5 yo) with a genetic diagnosis of A-T, that could be used in future early-life intervention trials.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A-T participants | Up to 4 longitudinal visits, depending on enrolment window Brain MRI/Assessment/Movement Quantitative Analysis/Blood Test | ||
| non A-T participants / Controls | One single visit Blood test only |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Brain MRI - Volumetric structural T1-weighted (T1) | Volume (mm³) - Acquisition parameters aligned to HEALthy Brain and Child Development Study (HBCD) | Up to 4 years ( last visit) |
| Brain MRI - Magnetic Resonance Spectroscopy (MRS): quantification of N-acetyl aspartate in the cerebellum | Chemical shift (ppm) - Acquisition parameters aligned to HEALthy Brain and Child Development Study (HBCD) | Up to 4 years ( last visit) |
| Brain MRI - Diffusion Weighted Imaging (DWI) | Apparent Diffusion Coefficient (mm²/s) - Acquisition parameters aligned to HEALthy Brain and Child Development Study (HBCD) | Up to 4 years ( last visit) |
| Neurological and developmental assessment |
| Up to 4 years ( last visit) |
| Quantitative movement analysis | Quantitative analysis of limb, facial and eye movements will be made using a machine learning approach. | Up to 4 years ( last visit) |
| Serum markers of neurodegeneration |
| Up to 4 years ( last visit) |
| Measure | Description | Time Frame |
|---|---|---|
| Lung MRI | • Lung MRI metrics, feasibility, and the results of the quantitative analyses, where it has been possible to do this.
| Up to 4 years ( last visit) |
| Natural sleep MRI procedure |
Not provided
Participants with A-T
Inclusion criteria
Exclusion criteria
NB - co-recruitment to other observational studies or trials is permitted. If a family chooses to enrol their child in an interventional study targeting neurodegeneration, provided that the intervention trial allows co-recruitment, we would like to retain the participant in the BOBCAT study until its conclusion. In this circumstance, the child's data would not be considered as part of the natural history dataset but would instead be used to demonstrate the feasibility of collecting longitudinal quantitative imaging and other biomarker data in people with A-T during infancy and early childhood.
Participants without A-T
Inclusion criteria
Exclusion criteria
Not provided
Not provided
Participants with A-T will be recruited principally via the National Paediatric A-T Clinic based at Nottingham University Hospitals NHS Trust. A second route for recruitment is the A-T Society, a UK charity that provides support and advocacy for people with A-T and their families.
Participants without A-T or other conditions described in the exclusion criteria, will be infants and young children undergoing general anaesthesia at Nottingham University Hospitals NHS Trust for minor surgical procedures (e.g. circumcision, orchidopexy) or diagnostic MRI.
Not provided
| ID | Term |
|---|---|
| D001260 | Ataxia Telangiectasia |
| ID | Term |
|---|---|
| D020754 | Spinocerebellar Ataxias |
| D002524 | Cerebellar Ataxia |
| D002526 | Cerebellar Diseases |
| D001927 | Brain Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood sample
Completion rates (%) and image quality (Signal-to-Noise Ratio, SNR, and Contrast-to-Noise Ratio CNR - unitless ) when using the sleep MRI protocol |
| Up to 4 years ( last visit) |
| D002493 |
| Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D020752 | Neurocutaneous Syndromes |
| D001259 | Ataxia |
| D020820 | Dyskinesias |
| D009461 | Neurologic Manifestations |
| D013684 | Telangiectasis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D000081207 | Primary Immunodeficiency Diseases |
| D049914 | DNA Repair-Deficiency Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |